Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Web – sheet or filament bases; compositions of bandages; or...
Reissue Patent
2007-05-01
2010-06-29
Fubara, Blessing M (Department: 1618)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Web, sheet or filament bases; compositions of bandages; or...
C424S443000, C424S446000, C424S447000
Reissue Patent
active
RE041408
ABSTRACT:
A method of effectively treating pain in humans is achieved by administering buprenorphine in accordance with first order kinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg/ml to about 1052 pg/ml is attained, and thereafter maintaining the administration of buprenorphine for at least an addition two-day dosing interval in accordance with substantially zero order kinetics, such that the patients experience analgesia throughout the at least two-day additional dosing interval.
REFERENCES:
patent: 3996934 (1976-12-01), Zaffaroni
patent: 4058599 (1977-11-01), Bauer et al.
patent: 4060084 (1977-11-01), Chandrasekaran et al.
patent: 4119713 (1978-10-01), Carosio
patent: 4262003 (1981-04-01), Urquhart et al.
patent: 4379454 (1983-04-01), Campbell et al.
patent: 4582835 (1986-04-01), Lewis et al.
patent: 4588580 (1986-05-01), Gale et al.
patent: 4673679 (1987-06-01), Aungst et al.
patent: 4784855 (1988-11-01), Yamashita et al.
patent: 4806341 (1989-02-01), Chien et al.
patent: 4879297 (1989-11-01), Mahjour et al.
patent: 4906463 (1990-03-01), Cleary et al.
patent: 4908027 (1990-03-01), Enscore et al.
patent: 4938759 (1990-07-01), Enscore et al.
patent: 4945103 (1990-07-01), Cohen
patent: 4956171 (1990-09-01), Chang
patent: 4983395 (1991-01-01), Chang et al.
patent: 4994278 (1991-02-01), Sablotsky et al.
patent: 5026556 (1991-06-01), Drust et al.
patent: 5028435 (1991-07-01), Katz et al.
patent: 5069909 (1991-12-01), Sharma et al.
patent: 5075341 (1991-12-01), Mendelson et al.
patent: 5090405 (1992-02-01), Jansen et al.
patent: 5091186 (1992-02-01), Miranda et al.
patent: 5132115 (1992-07-01), Wolter
patent: 5149538 (1992-09-01), Granger et al.
patent: 5176916 (1993-01-01), Yamanaka et al.
patent: 5225199 (1993-07-01), Hidaka et al.
patent: 5225440 (1993-07-01), London et al.
patent: 5236714 (1993-08-01), Lee et al.
patent: 5238933 (1993-08-01), Catz et al.
patent: 5240711 (1993-08-01), Hille et al.
patent: 5272149 (1993-12-01), Stalling
patent: 5306503 (1994-04-01), Muller et al.
patent: 5336210 (1994-08-01), Hidaka et al.
patent: 5342623 (1994-08-01), Enscore et al.
patent: 5344656 (1994-09-01), Enscore et al.
patent: 5352457 (1994-10-01), Jenkins
patent: 5462745 (1995-10-01), Enscore et al.
patent: 5486362 (1996-01-01), Kitchell et al.
patent: 5580876 (1996-12-01), Crain et al.
patent: 5613958 (1997-03-01), Kochinke et al.
patent: 5635203 (1997-06-01), Gale et al.
patent: 5683711 (1997-11-01), Fischer et al.
patent: 5700480 (1997-12-01), Hille et al.
patent: 5732717 (1998-03-01), Watanabe et al.
patent: 5785991 (1998-07-01), Burkoth et al.
patent: 5814032 (1998-09-01), Hori et al.
patent: 5817665 (1998-10-01), Dante et al.
patent: 5830505 (1998-11-01), Fischer et al.
patent: 5834010 (1998-11-01), Quan et al.
patent: 5837289 (1998-11-01), Grasela et al.
patent: 5843468 (1998-12-01), Burkoth et al.
patent: 5900420 (1999-05-01), Cole
patent: 5919473 (1999-07-01), Elkhoury
patent: 5942530 (1999-08-01), Panetta
patent: 5968547 (1999-10-01), Reder et al.
patent: 5989585 (1999-11-01), Bracher
patent: 6004969 (1999-12-01), Hu
patent: 6024974 (2000-02-01), Li
patent: 6024976 (2000-02-01), Miranda et al.
patent: 6096756 (2000-08-01), Crain et al.
patent: 6165499 (2000-12-01), Kleinsorgen et al.
patent: 6210699 (2001-04-01), Acharya et al.
patent: 6231886 (2001-05-01), Reder et al.
patent: 6242456 (2001-06-01), Shuster et al.
patent: 6264980 (2001-07-01), Hille
patent: 6280766 (2001-08-01), Becher et al.
patent: 6344212 (2002-02-01), Reder et al.
patent: 6391294 (2002-05-01), Dettmar et al.
patent: 6436977 (2002-08-01), Thompson
patent: 6554851 (2003-04-01), Palasis et al.
patent: 6595956 (2003-07-01), Gross et al.
patent: 6787149 (2004-09-01), El Khoury et al.
patent: 6865444 (2005-03-01), Howard
patent: 7011843 (2006-03-01), Becher et al.
patent: 7056527 (2006-06-01), Maruo et al.
patent: 7270830 (2007-09-01), Reidenberg
patent: 2001/0051186 (2001-12-01), Acharya et al.
patent: 2002/0137761 (2002-09-01), Crain et al.
patent: 2003/0104976 (2003-06-01), Davar et al.
patent: 2003/0114475 (2003-06-01), Fox et al.
patent: 2004/0146547 (2004-07-01), Marcenyac et al.
patent: 2004/0241218 (2004-12-01), Tavares
patent: 3526339 (1992-01-01), None
patent: 3546830 (1995-07-01), None
patent: 19840758 (2000-03-01), None
patent: 0368409 (1990-05-01), None
patent: 430019 (1991-06-01), None
patent: 432945 (1991-06-01), None
patent: 819438 (1998-01-01), None
patent: 821957 (1998-02-01), None
patent: 1422230 (2004-05-01), None
patent: 2165148 (1989-05-01), None
patent: 166095 (1995-03-01), None
patent: 9619975 (1994-12-01), None
patent: 95/01167 (1995-01-01), None
patent: 95/20393 (1995-08-01), None
patent: 96/19975 (1996-07-01), None
patent: 1997-004835 (1997-02-01), None
patent: 97/48380 (1997-12-01), None
patent: 1998-026780 (1998-06-01), None
patent: 98/36728 (1998-08-01), None
patent: 1999-012529 (1999-03-01), None
patent: 1999-032120 (1999-07-01), None
patent: 2000-035456 (2000-06-01), None
patent: 2002-070524 (2002-09-01), None
patent: 2002-085268 (2002-10-01), None
patent: 2003-079945 (2003-10-01), None
patent: 2004-103317 (2004-12-01), None
patent: 2005-011579 (2005-02-01), None
7.2 Buprenorphine, MNH/PAD/87.11, pp. 29-63 (1987).
BTDS List of Studies (Mar. 30, 2000).
Buprenorphine prescription withdrawn in Norway, available at http://www.drugscope.org.uk (Sep. 21, 2001).
Buprenorphine TDS Pre-NDA Meeting. Flux rate analysis of Buprenorphine transdermal delivery systems (BTDS) (Jun. 9, 1999).
Lasseter et al., Systemic pharmacokinetic (PK) study of buprenorphine (B) in mild to moderate chronic hepatic impairment (CHI). Amer Soc for Clin Phamcol and Therapeut. PI-4. (Feb. 2001).
Rigas et al., “Transdermal fentanyl: Practical use in the hospital and the home” ASHPMidyear Clinical Meetingv. 27 (1992).
The Safety of High Doses of Buprenorphine. Tables of Contents and Introduction (Feb. 22, 2002).
Cymbalta® ((duloxetine hydrochloride) Delayed-release Capsules)Physician's Desk Reference59thed., 2005.
Opana® ER ((Oxymorphone Hydrochloride) Extended Release Tablets)Physician's Desk Reference61sted., 2007.
Cranmer K., Laudau CJ, Friedman My Turner NG, Ripa SR. The Safety and tolerability 0 of 7-day buprenorphine TDS in the analgesic management of pain in the elderly—a six-month evaluation. www.ASCP.com/education/postersandpapersam05.com. Poster 34. (Study BUP3002S) (Nov. 2005).
Definition of “Aldehyde,” printed on Sep. 1, 2009 from Answers.com.
Definition of “Photoinitiator,” printed on Sep. 1, 2009 from Answers.com.
Definition of “Polymerize,” printed on Sep. 1, 2009 from Answers.com.
Definition of “Tannin,” printed on Sep. 1, 2009 from Wikipedia.org, the free cncyclopedia..
Bauer, KH (ed.)Pharmaceutische Technologiepp. 362-365 (1993).
Budd, K.,Experience with partial agonists in the treatment of cancer painin: Doyle, D (ed.),Opioids in the Treatment of Cancer Pain, Royal Society of Medicine Services International Congress and Symposium Series No. 146 (1990).
Burke et al., “Increased rates of drug abuse and dependence after onset of mood or anxiety disorders in adolescence”Hospital & Community Psychiatry45(5): 451-455 (1994) (Abstract only).
Curran et al., “Recognition and management of depression in a substance use disorder treatment population”American Journal of Drug & Alcohol Abuse33(4): 563-569 (2007) (Abstract only).
Currie et al., “Comorbidity of major depression with substance use disorders”Canadian Journal of Psychiatry50(10): 660-666 (2005).
Davis et al., “Major despression and comorbid substance use disorders”Current Opinions in Psychiatry21(1): 14-18 (2008).
Declaration of Prof. Jonathan Hadgraft dated Apr. 22, 2009.
Declaration of Prof. Jonathan Hadgraft dated Jul. 9, 2004.
Declaration of Prof. Jonathan Hadgraft dated Oct. 8, 2004.
Declaration of Prof. Jonathan Hadgraft dated Oct. 11, 2007.
Driscoll, CEPrimary Care14(2): 337-352 (1987).
Excerpt of Review for Approval issued Aug. 7, 1990 by
Goldenheim Paul D.
Kaiko Robert F.
Reder Robert F.
Duane Morris LLP
Fubara Blessing M
Purdue Pharma L.P.
LandOfFree
Method of providing sustained analgesia with buprenorpine does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of providing sustained analgesia with buprenorpine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of providing sustained analgesia with buprenorpine will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4177439